Since the first human cord blood transplant, performed 20 years ago, cord blood banks have been established worldwide for the collection and cryopreservation of cord blood for allogeneic hematopoietic stem cell transplant. A global network of cord blood banks and transplant centers has been established for a common inventory and study of clinical outcomes. Results of unrelated allogeneic cord blood transplants in malignant and nonmalignant diseases, in adults and children, show that, compared with HLAmatched unrelated BM transplant, cord blood has several advantages, including prompt availability of the transplant, decrease of GVHD and better long-term immune recovery resulting in a similar long-term survival. Several studies have shown that the number of cells is the most important factor for engraftment, although some degree of HLA mismatches is acceptable. Developments are expected to facilitate engraftment, including ex vivo expansion of stem cells, intrabone injection of cord blood cells and double cord blood transplants. In addition to hematopoietic stem cells, cord blood and placenta contain a large number of nonhematopoietic stem cells. In the absence of ethical concern, the unlimited supply of cells explains the increasing interest of using cord blood for developing regenerative medicine.
Introduction
The first cord blood transplant (CBT) was made possible by an intensive collaboration among three groups: AD. Auerbach from the Rockefeller University in New York (USA) described a method of prenatal diagnosis in Fanconi anemia (FA); 1 HE. Broxmeyer from Indiana University in Indianapolis (USA) systematically analyzed the number of hematopoietic cell progenitors in cord blood for the purpose of using the cells for hematopoietic reconstitution in humans; 2 and E. Gluckman from Hospital Saint Louis in Paris (France) showed that the in vivo hypersensibility of FA cells translated into an increased toxicity of the pretransplant-conditioning regimen used in aplastic anemia. Moreover, she was the first to use a modified attenuated dose conditioning in these patients with improved short-and long-term survival.
Since the first CBT, more than 20 000 CBTs have been reported worldwide and more than 400 000 cord blood units have been stored in more than 100 cord blood banks (source: Bone Marrow Donors Worldwide (BMDW), January 2009). The main practical advantages of using cord blood as an alternative source of stem cells are the relative ease of procurement, the absence of risks for mothers and donors, the reduced likelihood of transmitting infections, particularly CMV and the ability to store fully tested and HLA-typed transplants in the frozen state, available for immediate use.
These advantages were first recognized in CBT using related donors; secondarily, cord blood banks (CBB) established criteria for standardization of cord blood collection, banking, processing and cryopreservation for unrelated donor transplants in patients with various hematological malignant and non-malignant diseases.
Experimental background
The site of blood production changes during fetal development. 4, 5 In adults, the primary site of hematopoiesis is the BM. Ontogenically, hematopoiesis is first found in both extra embryonic sites (yolk sac) and intraembryonic sites (ventral aortic vessel); later, hematopoiesis is found in the liver and then in the BM. During fetal life, the cells circulate in blood and it is only after birth that they are found almost exclusively in the BM. These cells can be found in the adult circulation, but in concentrations of 10-100-fold fewer than those in the BM. The properties of fetal cells have been explored in the 1970s; the combination of features, hematopoietic activity and decreased immune reactivity made fetal liver cells an attractive source of stem cells for transplantation. 6 Later, this technique was abandoned because the success rate was low and the difficulty of procurement of fetal liver and the progress of allogeneic BM transplant stopped clinical studies on this subject. In the 1980s, after the Chernobyl catastrophe, research on alternative sources of stem cells, such as fetal and neonatal cells, was stimulated again, as a treatment of irradiation accidents. It was postulated by EA Boyse and HE Broxmeyer that UCB collected at birth might contain enough hematopoietic stem/progenitor cells for clinical use. This possibility was strengthened by the knowledge that hematopoietic progenitor cells from UCB could be maintained for many weeks in long-term cultures, suggesting their production from more primitive cells. Studies on mice in HE Boyse's laboratory showed that small amounts of embryonic neonatal blood, but not small amounts of adult blood, allowed the survival of approximately half of the lethally irradiated mice. This led to a multi-institutional study that addressed the following: (1) estimation of the reconstituting cellular content of cord blood by measurement of hematopoietic progenitor cell numbers and comparison with adult BM, as well as (2) collection, (3) transportation and (4) optimal cryopreservation of cord blood. They found in 101 samples, collected in New York and analyzed in the Indiana University School of Medicine, that the number of progenitors was in the lower range of numbers associated with successful engraftment and that the numbers were improved if there was no attempt at erythrocyte removal. They noted that samples could be successfully frozen, stored and thawed without major loss. 7 At that time, it was felt by this group that cord blood stem cells would be especially attractive for autologous purposes, making available for a recipient a perfectly matched set of stored cells in the future. However, it was unlikely that autologous cord blood transplantation would be tested in the near future. This concept led to a long-lasting debate on patenting cord blood for clinical use and of setting up commercial cord blood banks for personal use. Testing the concept of allogeneic cord blood stem cell transplants in which an HLA-identical sibling was available was discussed. The possibility of evaluating this situation in Fanconi anemia was suggested by Bo Dupont (Sloan Kettering Institute in New York) and was facilitated by AD Auerbach and H Friedman from Duke University. AD Auerbach selected pregnant mothers of FA patients; she made a prenatal diagnosis on cultured amniotic fluid cells and selected five mothers who were expecting a baby who was known, before birth, to be unaffected with FA and HLA identical to the patient. On the basis of the preceding information, umbilical cord blood was harvested and cryopreserved at birth. It was decided by all involved that the transplant should be performed in Paris under the direction of E. Gluckman because of her known expertise in the transplant of FA patients. It was felt by all involved and by the human subjects institutional review boards of the involved centers that the availability of cord blood in this case obviated the need for BM aspiration from the infant sibling, although the infant sibling was available for BM donation if necessary.
The first cord blood transplant
The first CBT was performed in 1988 in a patient with FA. 8 This patient had a healthy HLA-identical sibling who was shown by prenatal testing to be unaffected by the disorder, to have a normal karyotype and to be HLA identical to the patient. Her cord blood was collected at birth, cryopreserved and used after thawing for transplantation. The patient was conditioned by a procedure developed specifically for the treatment of FA patients who are extremely sensitive to the administration of alkylating agents such as CY. This patient was conditioned with CY 20 mg/kg and 5 Gy TLI. The frozen cells were hand delivered from Indiana to Paris in a dry shipper that maintained the temperature at À175 1C. The cells were thawed without further processing on day 0. The thawed cells were tested for viability, and progenitor assays and results were similar to the counts recorded before freezing. First signs of engraftment appeared on day 22, with subsequent complete hematological reconstitution and donor chimerism. The patient had no GVHD and is currently healthy with a complete long-term hematological and immunological donor reconstitution 20 years after CBT. Several aspects were identified as the subject of further questioning and investigations:
9,10 Would a single cord blood unit contain enough stem cells to permanently engraft children and adults? Would maternal cell contamination in fetal blood engraft and result in severe GVHD? Would the same results be obtained in patients transplanted for indications other than Fanconi anemia, such as leukemia? Would they also engraft in adults? Are the properties of hematopoietic cord blood cells different from adult cells? What are the immunological properties of cord blood cells? 11, 12 How does it interfere with GVHD, GVL and immune reconstitution? Is the immune immaturity of cord blood lymphocytes able to overcome the HLA barrier and authorize HLA-mismatched transplants? Is it possible to establish cord blood banks for unrelated and related transplants? What would be the criteria for collection, quality control and cryopreservation? Would it be possible to collect cord blood not only for familial transplant but also for unrelated transplants? What would be the size of this bank if it were demonstrated that HLA incompatibilities would not be recognized because of the immaturity of the immune system at birth? All these questions have been answered during the past 20 years thanks to the worldwide development of intense international cooperation, in Europe with Eurocord and Netcord, in the United States with CIBMTR and NMDP, and with Asia, Australia Cord and single transplant centers.
This first success opened the way to a new field in the domain of allogeneic HSCT as it showed that (1) a single umbilical cord blood contained enough hematopoietic stem cells to definitely reconstitute the host lympho-hematopoietic compartment; (2) an umbilical cord blood unit could be collected at birth without any harm to the newborn infant and (3) umbilical cord blood hematopoietic stem cells could be cryopreserved and transplanted in a myeloablated host after thawing without losing their repopulating capacity. Since then, our knowledge on the biological characteristics of umbilical cord blood cells has increased, emphasizing the advantages of using umbilical cord blood stem cells for transplant.
Milestones in the development of CBT
Optimization of UCB collection and storage. 2 First HLA-identical sibling cord blood transplant in a patient with Fanconi's anemia. 3 Development of CBB for related and unrelated transplants (Paris, Dusseldorf, New York, Milan).
13-15
History of cord blood transplantation E Gluckman
First unrelated mismatched cord blood transplant in children. 16 First unrelated cord blood transplant in adults. 17 Creation of the Eurocord Netcord network. 18 Description of criteria of donor choice based on the number of cells and possibility to use mismatched cord blood. [19] [20] [21] [22] [23] [24] Demonstration that in HLA-identical sibling transplants, cord blood gave delayed engraftment, less GVH and same survival. 25 Demonstration that, compared with matched unrelated BM, mismatched cord blood gave similar long-term leukemia-free survival in children 26 and adults.
27-29
Improvement of results mostly in adults by double cord blood transplants and non-myeloablative conditioning regimens.
30,31
Isolation of non-hematopoietic stem cells from cord blood as a first step for regenerative medicine.
Cord blood bank development
The progress in the field of UCBT is parallel with the huge interest in establishing and developing CBB worldwide. These banks have an important role in the process of UCBT. The Netcord group was created in 1998 to establish good practices in umbilical cord blood storage, to facilitate donor search, improve the quality of grafts, standardize excellence criteria on an international scale and, importantly, to establish procedures for bank accreditation. The inventory of Netcord, the cooperative network of large experienced UCB banks, currently has more than 200 000 cryopreserved UCB units ready for clinical use for unrelated recipients and more than 8624 grafts shipped; in the United States, NMDP has established a similar cord blood bank network. Collaborations between NetcordEurocord and NMDP have been established with the purpose of providing the most appropriate and highquality cord blood unit for a specific patient. We estimate that more than 400 000 cord blood units are available for transplantation in more than 100 cord blood banks in many countries (www.bmdw.org, assessed on November 2008). Summary of cord blood bank activity is presented in www.worldmarrow.org. National regulatory agencies and transplant centers are aware of the need for international standards, the major objectives of which are to promote quality throughout all phases of cord blood banking, with the objective of achieving a consistent production of high-quality placental and umbilical cord blood units for transplantation. These standards cover (1) collection of cord blood cells, regardless of the methodology or site of collection; (2) screening, testing and eligibility determination of the maternal and infant donor according to applicable law; (3) all phases of processing and storage, including quarantine, testing and characterization of the unit; (4) making the CB unit available for transplantation, either directly or through listing with a search registry; (5) the search process for selection of specific cord blood units; and (6) all transport or shipment of cord blood units, whether fresh or cryopreserved. All practical aspects of cord blood banking, such as mother's informed consent, collection techniques, labeling and identification, infectious disease and genetic disease testing, HLA typing, methodology of cell processing, cryopreservation, transportation and release have been extensively published. All these aspects are detailed in the last version of the Netcord-FACT Standards (www.factwebsite.org).
As the number of cord blood units is increasing, it seems that it is necessary to improve the quality of the units for the cost-efficient management of the banks. The optimal number of cord blood units is not really known, but should approach 9 for 10 000 inhabitants. Most banks prefer to bank only the largest units of more than 70 ml to obtain at least 3 Â 10 7 nucleated cells/kg. The effect of increasing the inventory from 50 000 to 300 000 cord blood units, with a minimum cell dose of 2.3 Â 10 7 /kg, results in an increase in the chance of finding a donor by 19% for children and by 10% for adults. Recently, S Querol et al. 32 showed that a bank containing 50 000 units is optimal for the United Kingdom, and larger banks would only marginally increase the chance of finding suitable units.
The current recommendations are to choose the following:
Cord blood units with p2 HLA disparities and 43 Â 10 7 nucleated cells/kg or X2 Â 10 5 CD34 þ cells/kg. In non-malignant disease, in which the risk of rejection is higher, the dose should be increased and one must avoid units with less than 3.5 Â 10 7 NC/kg and two or more HLA incompatibilities. If there is no single unit with these characteristics, look for two units with a combined total dose of X3 Â 10 7 NC/kg and, if possible, not more than one HLA difference between the two units and the patient.
Clinical experience with related and unrelated umbilical cord blood transplantation A survey of the International Bone Marrow Transplant registry (IBMTR) estimates that after 1998, 20% of stem cell transplants performed in young patients (o20 years old) are cord blood transplants (IBMTR Newsletter). In Japan, nowadays, approximately 50% of HSCTs from unrelated donors are being performed with cord blood cells.
Eurocord (www.eurocord.org) is an international registry that operates on behalf of the EBMT, which includes European and non-European centers, all performing either related or unrelated cord blood transplants. It works in close collaboration with EBMT and Netcord banks (www. netcord.org) to collect clinical data and follow up patients transplanted in or outside Europe with Netcord units.
Thanks to this collaboration, from 1988 to October 2008, 4875 UCBTs have been reported to Eurocord from 233 European transplant centers and 197 transplant centers from other countries. A total of 502 transplants have been reported using related donors (majority of HLA-identical sibling donors) mainly for children with malignant and non-malignant disorders and 4373 have been performed in an unrelated transplant setting for children (2901) and adults (1882). During the past 3 years, the number of unrelated UCBTs reported to Eurocord has increased, with 633 CBTs reported from EBMT to Eurocord in 2007. Some survival curves are shown in Figures 1 and 2 .
To promote education and information, Eurocord has recently launched a new European program entitled an On-line CME programme in cord blood technology and transplantation for providing a learning tool on the scientific, technical, clinical and regulatory aspects of cord blood, easily accessible at a time and language convenient for users www.eurocord-ed.org.
In a CIBMTR Eurocord study, comparing pediatric BM and CBTs from HLA-identical siblings, UCBT was associated with delayed granulocyte and platelet engraftment, reduced acute and chronic GVHD and same survival. This was the first analysis that demonstrated, unambiguously, that GVHD was reduced when CB cells were used instead of BM, even when it was provided by children. 25 This first study was the basis for advocating the use of mismatched UCBT and triggered the development of unrelated cord blood banks.
The second step was the demonstration that unrelated CBT could be used in all current indications of allogeneic HSCT, including malignant and nonmalignant diseases in children and adults. [33] [34] [35] [36] In children, with malignant diseases, two studies compared the outcome of unrelated UCBT and BMT. Eurocord published a study comparing the outcome of matched unrelated BMT (HLA 6 out of 6), either unmanipulated or T depleted, with mismatched UCBT. Results showed that after UCBT, engraftment was delayed, GVHD was reduced similar to T cell-depleted BMT and that relapse was the same; leukemia-free survival was also shown. 26 Eapen M et al. 37 compared outcomes of 503 children with acute leukemia, who were given an unrelated mismatched UCBT, with 282 unrelated BM transplant recipients (116 HLA allele matched 8 out of 8). HLA allelemismatched BM recipients had more acute and chronic GVHD without decreasing leukemia-free survival (LFS). Importantly, they found that even while using an allelematched BM donor, LFS was not statistically different from one or two HLA-disparate UCBTs and that an HLAmatched UCBT recipient had better outcomes compared with HLA allele-matched BM recipients. However, an increased transplant-related mortality was observed in children transplanted with a low CB cell dose (o3 Â 10 7 /kg) and one HLA-disparate CB graft or in children given a 2 HLA-disparate UCBT independently of the cell dose infused. Interestingly, use of 2 HLA-mismatched UCBTs was associated with a lower incidence of relapse.
The same studies were performed in adults with malignancies. The Eurocord study compared adults with acute leukemia receiving either a matched unrelated BM transplant (HLA 6 out of 6) or a mismatched cord blood transplant. Results showed that, despite a delay in engraftment, CBT demonstrated a similar leukemia survival than did BMT. 27 In the same issue of the journal, CIBMTR and New York City Blood Bank showed that, in adults with malignancies, CBT demonstrated the same LFS survival than did 1 Ag-mismatched UBMT. 28 At the same time, a Japanese study showed that CBT yielded better results than did MUD. 29 In a meta analysis, combining published studies, 161 children and 316 adults undergoing UCBT (mostly 1 or 2 Ag mismatched), along with 316 children and 996 adults undergoing UBMT (almost entirely fully matched with the recipient), were analyzed. T-celldepleted UBMT was excluded; where data were available, only fully matched UBMT was used in the analysis. Pooled comparisons of studies of UCBT and UBMT in children found that the incidence of chronic GVHD was lower with UCBT, but the incidence of grade III-IV acute GVHD did not differ. There was no difference in 2-year overall survival in children when studies were pooled. For adults, transplantation-related mortality and LFS were not statistically different. 33 Recently, Eurocord and CIBMTR conducted a study comparing the outcome of unrelated HLA-matched or 1-2 antigens-mismatched BM (n ¼ 364) or G-CSF-mobilized peripheral blood (n ¼ 728) with mismatched cord blood transplant (n ¼ 148) in adults with acute leukemia. In multivariate analysis, in UCBT, transplantation-related mortality was higher but the relapse rate and GVHD were lower, resulting in the same LFS compared with the other sources of stem cells (unpublished results). The results of these comparative studies and of the meta-analysis together showed that (1) UCBT is feasible in adults when a cord 
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Figure 2 Three-year overall survival for unrelated cord blood transplants according to the period (before and after 1998).
History of cord blood transplantation E Gluckman blood unit contains a higher number of cells and should be considered an option as an allogeneic stem cell source for patients lacking an HLA-matched BM donor. (2) Despite increased HLA disparity, UCB from unrelated donors offers sufficiently promising results to matched UBM in adults with hematological malignancies, leading to the conclusion, as in children, that the donor search process for BM and UCB from unrelated donors should be started simultaneously, especially in patients with acute leukemia, in whom the time factor is crucial.
Conclusion
Much has been learned in a relatively short time on the properties of cord blood hematopoietic progenitors and their clinical application. Cord blood transplant needs to meet several new challenges. First, several methods of improvement of the speed of engraftment and decreasing transplant-related mortality are investigated, such as the increase of donor pool to decrease the number of HLA mismatches or the use of double cord blood transplants.
Other methods are currently investigated, such as cord blood intrabone infusion, ex vivo expansion with cytokine cocktails or homing factors. More interestingly, non-hematopoietic stem cells have been isolated from cord blood and placenta. These cells can be grown and differentiated in various tissues including MSC, bone, cartilage, liver, pancreas, neurones, endothelial cells, muscle, keratinocytes and so on. They have an advantage over other sources of stem cells, such as embryonic stem cells or induced pluripotent stem cells, because their supply is unlimited, they can be used in autologous or allogeneic situations, they need minimal manipulation and they raise no ethical concerns. Future studies will, in the near future, test the potential of cord blood cells for the treatment of several diseases including, among other possibilities, diabetes, arteritis, burns, neurological disorders and myocardial infarction.
